SHANGHAI, China I August 1, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over ...

STUTTGART, Germany I August 02, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis.

The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...

Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of ...

EMERYVILLE, CA, USA I July 31, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company ...

TAIPEI, Taiwan I August 1, 2025 I Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration ...

EAST HANOVER, NJ, USA I July 31, 2025 I Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

NORTH CHICAGO, IL, USA I July 30, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 ...